299 related articles for article (PubMed ID: 29366520)
41. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance.
Lu F; Dong Y; Li Q; Wang M
Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
43. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
[TBL] [Abstract][Full Text] [Related]
44. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
[TBL] [Abstract][Full Text] [Related]
45. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.
Du Y; Nie L; Xu L; Wu X; Zhang S; Xue J
Scand J Immunol; 2020 Jul; 92(1):e12884. PubMed ID: 32243638
[TBL] [Abstract][Full Text] [Related]
46. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
47. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
[TBL] [Abstract][Full Text] [Related]
48. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
Yang J; Hu M; Bai X; Ding X; Xie L; Ma J; Fan B; Yu J
Medicine (Baltimore); 2019 Sep; 98(39):e17231. PubMed ID: 31574833
[TBL] [Abstract][Full Text] [Related]
49. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
50. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
Nakazawa T; Adachi S; Kitano M; Isobe Y; Kokubu S; Hidaka H; Ono K; Okuwaki Y; Watanabe M; Shibuya A; Saigenji K
Oncology; 2007; 73(1-2):90-7. PubMed ID: 18337620
[TBL] [Abstract][Full Text] [Related]
51. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Sorensen SF; Demuth C; Weber B; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Oct; 100():77-84. PubMed ID: 27597284
[TBL] [Abstract][Full Text] [Related]
52. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
[TBL] [Abstract][Full Text] [Related]
53. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
[TBL] [Abstract][Full Text] [Related]
54. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
55. Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.
Zhang J; Zhang H; Luo Y
Med Sci Monit; 2019 Feb; 25():1275-1282. PubMed ID: 30771277
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy.
Matsuo Y; Yoshida K; Nishimura H; Ejima Y; Miyawaki D; Uezono H; Ishihara T; Mayahara H; Fukumoto T; Ku Y; Yamaguchi M; Sugimoto K; Sasaki R
J Radiat Res; 2016 Sep; 57(5):512-523. PubMed ID: 27053259
[TBL] [Abstract][Full Text] [Related]
57. Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion.
Hou JZ; Zeng ZC; Zhang JY; Fan J; Zhou J; Zeng MS
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):362-8. PubMed ID: 22381903
[TBL] [Abstract][Full Text] [Related]
58. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
[TBL] [Abstract][Full Text] [Related]
59. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Cubillos-Zapata C; Martínez-García MÁ; Campos-Rodríguez F; Sánchez de la Torre M; Nagore E; Martorell-Calatayud A; Hernández Blasco L; Chiner Vives E; Abad-Capa J; Montserrat JM; Cabriada-Nuño V; Cano-Pumarega I; Corral-Peñafiel J; Diaz-Cambriles T; Mediano O; Somoza-González M; Dalmau-Arias J; Almendros I; Farré R; López-Collazo E; Gozal D; García-Río F;
Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30487198
[TBL] [Abstract][Full Text] [Related]
60. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
